Stockscreener 앱 받기
2.87
0.70%
0.02
시장 영업 전:
2.85
-0.02
-0.70%
전일 마감가:
$2.85
열려 있는:
$2.82
하루 거래량:
668.86K
Relative Volume:
0.45
시가총액:
$255.09M
수익:
$58.36M
순이익/손실:
$-25.72M
주가수익비율:
-7.8824
EPS:
-0.3641
순현금흐름:
$-24.91M
1주 성능:
+14.34%
1개월 성능:
-10.87%
6개월 성능:
-47.72%
1년 성능:
-26.97%
1일 변동 폭
$2.79
$2.895
1주일 범위
$2.465
$2.97
52주 변동 폭
$2.20
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
2.87 | 255.09M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
The 14% return this week takes Aquestive Therapeutics' (NASDAQ:AQST) shareholders three-year gains to 105% - simplywall.st
Geode Capital Management LLC Trims Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Russell Investments Group Ltd. Has $386,000 Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Check out these key findings about Aquestive Therapeutics Inc (AQST) - Sete News
Is Aquestive Therapeutics Inc (AQST) worth investing in despite its overvalued state? - uspostnews.com
Recent Insider Activity Suggests Potential Gains for Aquestive Therapeutics Inc (AQST) - knoxdaily.com
Investor’s Delight: Aquestive Therapeutics Inc (AQST) Closes Strong at 2.58, Up 2.79 - DWinneX
Does Aquestive Therapeutics Inc (NASDAQ: AQST) Still Need To Convince Analysts? - Stocksregister
Vanguard Group Inc. Grows Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Wellington Management Group LLP Has $639,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive completes marketing application for Anaphylm in U.S. - MSN
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - The Manila Times
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - GlobeNewswire Inc.
Raymond James Financial Inc. Invests $498,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World
HC Wainwright Reaffirms “Buy” Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World
New Jersey Pharma Co. Shares Positive Pediatric Study - streetwisereports.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by HighTower Advisors LLC - Defense World
Aquestive’s Anaphylm shows promise in pediatric study By Investing.com - Investing.com South Africa
Aquestive’s Anaphylm shows promise in pediatric study - Investing.com India
Aquestive stock gains as Anaphylm NDA completes (AQST:NASDAQ) - Seeking Alpha
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Benzinga
Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating - TipRanks
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film - BioSpace
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA - TipRanks
Aquestive Therapeutics Announces Positive Topline PK Results From Its Pediatric Study And Completes The NDA Submission For Anaphylm™ (Epinephrine) Sublingual Film - MENAFN.com
Charles Schwab Investment Management Inc. Grows Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive stock falls amid Libervant approval, Anaphylm update - MSN
Bank of New York Mellon Corp Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha
Aquestive Therapeutics: Not For Me, But Attractive (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark - simplywall.st
What is HC Wainwright’s Forecast for AQST FY2026 Earnings? - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright - Defense World
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Aquestive Therapeutics Advances Product Pipeline and Market Access - TipRanks
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call Transcript - Insider Monkey
Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations - TipRanks
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
1.80%
자본화:
|
볼륨(24시간):